Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer

Tomasz M. Beer, Eugene D. Kwon, Charles G. Drake, Karim Fizazi, Christopher Logothetis, Gwenaelle Gravis, Vinod Ganju, Jonathan Polikoff, Fred Saad, Piotr Humanski, Josep M. Piulats, Pablo Gonzalez Mella, Siobhan S. Ng, Dirk Jaeger, Francis X. Parnis, Fabio A. Franke, Javier Puente, Roman Carvajal, Lisa Sengeløv, M. Brent McHenryArvind Varma, Alfonsus J. Van Den Eertwegh, Winald Gerritsen

Research output: Contribution to journal › Article › peer-review

539 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences